DealForma put together a comprehensive overview in the Biopharma Q2 2024 Deals and Venture Update. This report offers detailed insights into the latest trends and activities in the healthcare and life sciences sectors. It covers crucial topics such as deal activity within these industries, insights into licensing agreements with major pharmaceutical companies, and highlights of top dealmakers. Get your FREE report now!
This report includes
Biopharma Licensing Activity
Top Dealmakers
Top Therapy Areas and Modalities
Biopharma Venture Activity
Biopharma IPOs
Biopharma M&A
Our Q2 2024 cancer review delves into significant R&D partnerships, M&As, and ventures reflecting strong activity for the sector. PeptiDream and Novartis expanded their peptide-drug
Our Q2 2024 cancer review delves into R&D and licensing partnership activity, investments, IPOs and M&A. In R&D, PeptiDream expanded its peptide-drug conjugate partnership with
Our H1 2024 analysis of the cardiovascular sector explores notable M&As, R&D partnerships, and ventures. Johnson & Johnson completed a $13.1 billion acquisition of Shockwave
